SSTR4 Agonists via 3-Aza-Bicyclic Core Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective somatostatin receptor subtype 4 (SSTR4) agonists that exhibit high stability and oral efficacy, particularly non-peptidic agonists with reduced side effects due to high selectivity for SSTR4 over other receptor subtypes.
Innovation Solution
Development of 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives that act as agonists for SSTR4, providing high metabolic stability and selectivity for SSTR4 receptors, thereby reducing the likelihood of side effects and enhancing pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If non-peptidic agonists are developed for SSTR4, then metabolic stability is improved, but selectivity over other receptor subtypes deteriorates
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the bicyclic core structure. Different substituents (R1-R6) are placed at specific locations to optimize both metabolic stability and receptor selectivity simultaneously, rather than treating the molecule as a uniform entity
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, ring fusion configurations, and stereochemistry to achieve the desired balance between metabolic stability and selectivity. Specific embodiments demonstrate how modifying these parameters leads to improved compound performance
2Object-affected harmful factors
If high selectivity for SSTR4 is achieved, then side effects are reduced, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional regions: a bicyclic core providing structural stability and selectivity, and substituent groups (R1-R6) that can be independently optimized. This modular approach allows systematic development while managing complexity
Solution Approach 2:
The patent achieves universality through a platform approach where the bicyclic core structure serves multiple functions: providing metabolic stability, enabling receptor selectivity, and allowing for diverse substituent combinations. This multi-functional core simplifies the overall development process
3Ease of operation
If oral efficacy is improved, then bioavailability increases, but metabolic stability may deteriorate
Solution Approach 1:
The patent employs parameter changes by modifying physicochemical properties such as lipophilicity, molecular weight, and hydrogen bonding capacity through specific substituent selections. These parameter adjustments optimize oral absorption while maintaining metabolic stability
Data Source
AI summary
3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.